Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). Primary ...

Bremelanotide is used as needed prior to anticipated sexual activity. Palatin Technologies announced that the New Drug Application (NDA) for bremelanotide has been submitted to the Food and Drug ...

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study. In ...

The drug, called bremelanotide (brand name Vyleesi) has been approved to treat premenopausal women with hypoactive sexual desire disorder (HSDD), a condition in which low sexual desire causes personal ...

~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated ...

Palatin Technologies (NYSE:PTN) said it started enrollment in a phase 2b trial of bremelanotide to treat diabetic kidney disease. The company added that patient screening/enrollment had begun in ...

WALTHAM, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that new and encore data related to bremelanotide and Hypoactive Sexual Desire Disorder ...

CRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of ...

CRANBURY, N.J., Sept. 10, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the ...

Dec. 1, 2006 &#151; -- What is desire? What triggers it? And how can we make it last? Some people think oysters, chocolate and ginseng -- among other mythical things --are aphrodisiacs. They are rich ...